Cover Image
市場調查報告書

腸胃炎 :開發平台分析

Gastroenteritis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 200947
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
腸胃炎 :開發平台分析 Gastroenteritis - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 49 Pages
簡介

所謂腸胃炎是指腸胃的感染疾病症狀有胃痛、痙攣、發燒、噁心、頭痛等。 原因有受污染的飲料食品和與帶有病毒的人類接觸等。

本報告提供腸胃炎的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃等相關資訊。以及最新的新聞和發表等資訊。

簡介

腸胃炎 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Bharat Biotech International Limited
  • Cocrystal Pharma, Inc.
  • RedHill Biopharma Ltd.
  • Takeda Pharmaceutical Company Limited
  • UMN Pharma Inc.

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders
  • norovirus (bivalent) vaccine
  • ondansetron hydrochloride CR
  • ORV-116E
  • Small Molecules to Inhibit RNA Dependent RNA Polymerase for Acute Gastroenteritis
  • UMN-2002
  • UMN-2003

最近的開發平台趨勢

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8558IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastroenteritis - Pipeline Review, H2 2016, provides an overview of the Gastroenteritis (Gastrointestinal) pipeline landscape.

Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water, and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastroenteritis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastroenteritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastroenteritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastroenteritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively for Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively for Gastroenteritis.

Gastroenteritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastroenteritis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Gastroenteritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastroenteritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastroenteritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastroenteritis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastroenteritis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastroenteritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Gastroenteritis Overview
  • Therapeutics Development
    • Pipeline Products for Gastroenteritis - Overview
    • Pipeline Products for Gastroenteritis - Comparative Analysis
  • Gastroenteritis - Therapeutics under Development by Companies
  • Gastroenteritis - Therapeutics under Investigation by Universities/Institutes
  • Gastroenteritis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Gastroenteritis - Products under Development by Companies
  • Gastroenteritis - Products under Investigation by Universities/Institutes
  • Gastroenteritis - Companies Involved in Therapeutics Development
    • Nanotherapeutics, Inc.
    • RedHill Biopharma Ltd.
    • Takeda Pharmaceutical Company Limited
    • UMN Pharma Inc.
  • Gastroenteritis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Antibodies for Gastroenteritis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibodies to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • norovirus (bivalent) virus like particle vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ondansetron hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMN-2002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UMN-2003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Gastroenteritis - Product Development Milestones
    • Featured News & Press Releases
      • Jun 20, 2016: Takeda Initiates Worlds First Norovirus Vaccine Field Trial
      • Mar 01, 2016: RedHill Biopharma Provides Update on RHB-102
      • Oct 14, 2015: RedHill Biopharma Provides Update on BEKINDA Ongoing Phase III Study for Gastroenteritis and Announces Planned Phase II Study for IBS-D
      • Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting
      • Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis
      • Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support
      • Sep 03, 2014: RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis
      • Dec 08, 2011: The New England Journal Of Medicine Publishes Study Showing LigoCyte's Norovirus Vaccine Demonstrates Protection Against Illness
      • Oct 25, 2010: LigoCyte Presents Positive Results From Norovirus Vaccine Challenge Study At IDSA Annual Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Gastroenteritis, H2 2016
  • Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Gastroenteritis - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Gastroenteritis - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Gastroenteritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Gastroenteritis - Pipeline by UMN Pharma Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016

List of Figures

  • Number of Products under Development for Gastroenteritis, H2 2016
  • Number of Products under Development for Gastroenteritis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top